Officials with the FDA have approved Nivagen Pharmaceuticals’ succinylcholine chloride injection USP 200 mg/10 mL. The prescription drug is indicated for facilitating tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Adverse effects of succinylcholine chloride injection include anaphylaxis, hyperkalemia, and malignant hyperthermia.

According to the FDA, the agency recognizes the increased demand for certain products during the coronavirus disease 2019 (COVID-19) pandemic, and it remains deeply committed to facilitating access to medical products to help address critical needs of the American public.


REFERENCE

Coronavirus (COVID-19) Update: Daily Roundup May 19, 2020 [news release]. Silver Spring, MD; May 19, 2020: FDA website. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-19-2020 Accessed May 20, 2020.